HC Wainwright Has Bullish Forecast for Altimmune Q3 Earnings

Altimmune, Inc. (NASDAQ:ALT) – Analysts at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for shares of Altimmune in a research report issued on Wednesday, August 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.26) for the quarter, up from their prior estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Altimmune’s Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.06) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.27) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at $1.27 EPS.

Several other research firms have also weighed in on ALT. William Blair restated a “market perform” rating on shares of Altimmune in a research report on Friday, June 27th. Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. JMP Securities dropped their price target on Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a research report on Thursday, July 10th. The Goldman Sachs Group upgraded Altimmune to a “strong sell” rating in a research report on Thursday, July 10th. Finally, UBS Group dropped their price target on Altimmune from $26.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Altimmune currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.40.

Altimmune Price Performance

Shares of ALT stock opened at $3.63 on Friday. The firm has a market cap of $320.38 million, a P/E ratio of -3.08 and a beta of -0.01. Altimmune has a fifty-two week low of $2.90 and a fifty-two week high of $11.16. The business’s 50 day moving average price is $4.75 and its 200-day moving average price is $5.28. The company has a debt-to-equity ratio of 0.09, a quick ratio of 15.85 and a current ratio of 20.44.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its stake in shares of Altimmune by 69.3% in the fourth quarter. Wells Fargo & Company MN now owns 215,538 shares of the company’s stock worth $1,554,000 after purchasing an additional 88,209 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Altimmune in the fourth quarter worth $472,000. Bank of America Corp DE raised its stake in shares of Altimmune by 21.7% in the fourth quarter. Bank of America Corp DE now owns 181,889 shares of the company’s stock worth $1,311,000 after purchasing an additional 32,382 shares during the last quarter. Bellevue Group AG raised its stake in shares of Altimmune by 9.5% in the fourth quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock worth $6,817,000 after purchasing an additional 81,786 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Altimmune by 5.7% in the fourth quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock worth $4,801,000 after purchasing an additional 35,918 shares during the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.